オプションチェーンは、Nuvectis Pharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Nuvectis Pharmaの市場センチメントを評価します。.

Nuvectis Pharma (NASDAQ:NVCT) 株価情報, オプションチェーン

Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Nuvectis Pharma Inc

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) researcher Troy Teslike expects the EV giant to sell just 21,000 Cybertrucks in 2025, lower than the sales of the stainless steel truck in 2024.
What Happened: &#8220;Wall Street analysts estimate 65,000 Cybertruck sales in 2025, but I expect 21,000 units,&#8221; Teslike said in a post on social media platform X, formerly Twitter. 
Teslike, who tracks the EV giant&#8217;s delivery numbers, pegs Cybertruck deliveries for 2024 at 34,426 units. This, however, includes customers who had pre-ordered the vehicle and had been awaiting it since the vehicle was unveiled in November 2019, Teslike noted. 
&#8220;The order backlog is gone. Tesla ended 2024 with 10,600 unsold Cybertrucks because of too much production and low demand,&#8221; the researcher said while also dismissing the possibility of a cheaper Cybertruck variant launch this year. 
&#8220;A cheaper Cybertruck this year is unlikely because the Cybertruck is not profitable. A cheaper version would make things worse,&#8221; he said. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wall Street analysts estimate 65,000 Cybertruck sales in 2025, but I expect 21,000 units. Deliveries were 34,426 units in 2024. However, this included many buyers who had been waiting since the reveal event in November 2019. The order backlog is gone. Tesla ended 2024 with…
&mdash; Troy Teslike (@TroyTeslike) <a href="https://twitter.com/TroyTeslike/status/1886077162056253791?ref_src=twsrc%5Etfw">February 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Tesla started delivering the Cybertruck in the U.S. four years after unveiling it in November 2023. The company sold only its limited edition foundation series initially, priced nearly $20,000 more than the non-foundation series of the truck. The non-foundation series Cybertucks started to be sold only in the fourth quarter of 2024. 
The non-foundation series Cybertruck is presently available in two variants. The lower-priced all-wheel drive variant starts at $79,990 and the higher-priced Cyberbeast variant at $99,990.
However, during its <a href="https://www.benzinga.com/24/12/42262279/a-year-after-teslas-first-cybertruck-deliveries-the-truck-has-a-long-way-to-go-to-meet-musks-goals">unveiling in November 2019</a>, Tesla said it would have three variants of the truck with the entry-level single-motor, rear-wheel-drive (RWD) version starting at $39,900, the dual motor all-wheel drive variant projected to begin at $49,900 and the top tier tri-motor all-wheel drive at $69,900. The price point, higher than what was projected at the time of unveiling, is seemingly deterring potential customers and reservation holders from buying the vehicle. 
However, Tesla is now selling the Cybertruck in <a href="https://www.benzinga.com/news/24/08/40276652/tesla-cybertruck-reportedly-drives-into-canada-reservation-holders-get-invites-to-configure-their-or">Canada and Mexico </a>in addition to the U.S. On Monday, the company also announced that the all-wheel drive variant of the vehicle is now eligible for a <a href="https://www.benzinga.com/tech/25/02/43455539/teslas-cybertruck-just-got-more-affordable-thanks-to-7500-tax-credit">federal EV tax credit of $7,500</a> in the U.S., taking the effective price for eligible customers down to $72,490.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43455022/fords-mustang-mach-e-was-its-saving-grace-in-january-as-sales-of-its-other-evs-dipped">Mustang Mach-E Accelerates Ford&#8217;s EV Sales In January Even As F-150 Lightning Slows Down</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

News

Tech

TSLA

Tesla Cybertruck Headed For A Sales Crash In 2025? Analyst Sounds The Alarm, Predicts Elon Musk-led EV Giant Will Move Less Than A Third Of Street Estimates

B of A Securities analyst Mariana Perez Mora maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Buy and raises the price target from $90 to $125.

Price Target

Analyst Ratings

PLTR

B of A Securities Maintains Buy on Palantir Technologies, Raises Price Target to $125

UBS analyst Manav Gupta downgrades Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Neutral to Sell and lowers the price target from $20.5 to $15.

Downgrades

CLMT

UBS Downgrades Calumet to Sell, Lowers Price Target to $15

Jefferies analyst Randal Konik maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Hold and lowers the price target from $15 to $12.

Jefferies Maintains Hold on Kohl's, Lowers Price Target to $12

Jefferies analyst Randal Konik downgrades Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Buy to Hold and lowers the price target from $125 to $111.

OLLI

Jefferies Downgrades Ollie's Bargain Outlet to Hold, Lowers Price Target to $111

Jefferies analyst Randal Konik downgrades Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) from Buy to Hold and lowers the price target from $4 to $1.6.

BRLT

Jefferies Downgrades Brilliant Earth Group to Hold, Lowers Price Target to $1.6

Jefferies analyst Brent Thill maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Underperform and raises the price target from $28 to $60.

Jefferies Maintains Underperform on Palantir Technologies, Raises Price Target to $60

Valens secures 'Alliance partner' status with the renowned professional audio solutions company Sennheiser

Sennheiser Teams Up With Valens Semiconductor to Elevate TeamConnect Bar Flexibility And Performance

<ul>
<li>Vertical completes Phase 2 of its piloted thrustborne testing with the VX4 prototype exceeding expectations for stability and performance</li>
<li>The company is now preparing for the next stage in its testing programme – piloted wingborne flight – a world first for a full-scale tilt rotor eVTOL</li>
<li>Update comes as Vertical continues its strong start to the year – including securing $90m in its recent upsized public offering</li>
</ul>

EVTL

Vertical Aerospace Achieves Key Milestone As VX4 Prototype Excels In Piloted Thrustborne Testing

The phased rollout of Viasat's high-speed, reliable in-flight Wi-Fi service will span STARLUX's entire active fleet. In total, 48 aircraft, including Airbus A330-900s, A321neos, A350-900 and A350-1000 aircraft will install or transition to Viasat's most advanced connectivity system, based on the ViaSat-3 compatible and multi-orbit ready high-performance GM-40 terminal solution. The rollout will encompass both factory installs and expedited retrofits.

VSAT

STARLUX Enhances Sky-High Connectivity With Viasat's Advanced Satellite Solutions, Covering 48 Aircraft

Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) is scheduled to report its third-quarter earnings after market close on Tuesday.
Earnings Estimates: Analysts are expecting revenue of $2.3 billion, down from $2.37 billion in the prior period, according to <a href="http://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
The video game publisher enters the <a href="https://www.benzinga.com/25/01/43172028/electronic-arts-has-limited-growth-potential-says-analyst">earnings report under increased scrutiny</a> after BofA Securities downgraded the stock to Neutral from Buy on Jan. 23, cutting its price target to $130 from $170. 
What Analysts Are Saying: The downgrade centered on concerns about EA&#8217;s ability to drive growth in the PC/Console gaming market, particularly regarding its flagship FC soccer franchise, which accounts for approximately 60% of its operating income.
Preliminary third-quarter revenue came in at $1.883 billion, falling significantly short of the $2.507 billion analysts had expected. 
See Also: <a href="https://www.benzinga.com/25/02/43455760/pfizer-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Pfizer Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
The <a href="https://www.benzinga.com/quote/EA/analyst-ratings">consensus among analysts</a> remains cautiously optimistic, with an average price target of $151.96 based on 26 ratings, suggesting a potential upside from current levels of around $123.
Key Items to Watch: The Redwood City, California-based gaming giant faces questions about its FC franchise&#8217;s performance, with BofA noting a potential double-digit year-over-year decline in Live Services bookings. However, analysts note that recent weakness since November could be attributed to seasonal factors rather than long-term structural issues.
EA shares are trading well below their 52-week high of $168.50, with a Relative Strength Index of 31 indicating oversold conditions. The company maintains a market capitalization of $32.37 billion and a price-to-earnings ratio of 31.52.
Price Action: EA stock closed at $122.91 on Monday. In pre-market trading, the stock edged up 0.41% to $123.41. Year to date, EA has declined 15.76%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43452860/palantir-soars-23-after-hours-as-cramer-says-i-wont-let-you-down-and-dan-ives-calls-it-the-next-oracle-in-ai-boom">Palantir Crosses $100 Mark In After-Hours Trading, Hits All-Time High — Jim Cramer Says &#8216;Won&#8217;t Let You Down&#8217;</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Earnings

Equities

Markets

Electronic Arts Set To Report Q3 Earnings Amid Analyst Downgrade, FC Franchise Concerns, 16% Year-To-Date Stock Decline

Microsoft Corporation&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) founder Bill Gates said that it could take three to five years to develop logical quantum computing qubits while immediately adding that the timeline could be longer. 
What Happened: Gates, who is invested in the quantum computing company IonQ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) through his venture Breakthrough Energy, spoke about the quantum computing companies <a href="https://finance.yahoo.com/news/bill-gates-theres-a-possibility-quantum-computing-will-become-useful-in-3-to-5-years-152007398.html">during</a> Yahoo Finance&#8217;s Opening Bid podcast.
He explained that Huang&#8217;s prediction may be incorrect but it&#8217;s possible that within three to five years, one of these quantum computing techniques will achieve sufficient logical qubits to solve complex problems.
However, Gates immediately went on to say &#8220;But Jensen&#8217;s correct, it could take longer, this is both in terms of how you build a quantum computer and what software you write that can solve problems that other computers couldn&#8217;t write.&#8221;
Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) and IonQ were up on Monday. Quantum computing stocks have declined on a year-to-date basis. The exchange-traded fund that tracks quantum computing stocks Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>) declined 0.52% on Monday and 0.63% year-to-date. However, stocks were up in pre-market trading on Tuesday, with the exception of IonQ. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>Monday&#8217;s Performance</td>
<td>Tuesday Pre-Market Performance</td>
<td>YTD Performance</td>
</tr>
<tr>
<td>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)</td>
<td>2.28%</td>
<td>1.56%</td>
<td>-32.65%</td>
</tr>
<tr>
<td>Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>)</td>
<td>-4.14%</td>
<td>2.61%</td>
<td>-46.96%</td>
</tr>
<tr>
<td>D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)</td>
<td>-3.03%</td>
<td>2.26%</td>
<td>-40.06%</td>
</tr>
<tr>
<td>IonQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)</td>
<td>5.01%</td>
<td>-0.19%</td>
<td>-3.78%</td>
</tr>
<tr>
<td>Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>)</td>
<td>-0.52%</td>
<td>1.36%</td>
<td>-0.63%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/news/events/25/02/43455326/illumina-stock-tumbles-nearly-5-overnight-on-robinhood-as-china-adds-ilmn-calvin-klein-owner-pvh-to-unreliable-entities-list-amid-trade-war-with-us">Illumina Stock Tumbles Nearly 5% Overnight On Robinhood As China Adds ILMN, Calvin Klein Owner PVH To &#8216;Unreliable Entities List&#8217; Amid Trade War With US</a>
Why It Matters: Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang during CES 2025 <a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">predicted</a> that practical quantum computing is 15-30 years away. This was accompanied by similar skepticism from Meta Platform Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg, <a href="https://www.benzinga.com/markets/equities/25/01/42939766/quantum-computing-stocks-tumble-after-mark-zuckerberg-backs-nvidia-ceo-jensen-huangs-practical-comments-qubt-down-9-rgti-falls-16-and-ionq-loses-15">calling</a> quantum computing "still quite a ways off from being a truly practical paradigm,&#8221; during a podcast.
Gates, during the interaction, went on to say &#8220;I am thrilled that MSFT is making those investments but there is a great deal of uncertainty there.&#8221;
However, he added that rapid and predictable advancements in artificial intelligence over the next three to five years promise significant capabilities.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43454291/winner-winner-chicken-dinner-tyson-foods-q1-beat-showcases-improved-execution-in-poultry-says-ceo" target="_blank" rel="noreferrer noopener">Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases ‘Improved Execution' In Poultry, Says CEO</a></li>
</ul>
Photo courtesy: Shutterstock

Sector ETFs

ETFs

IONQ

MSFT

NVDA

QBTS

QTUM

QUBT

RGTI

Bill Gates Says Nvidia's Jensen Huang 'Could Be Wrong' About Quantum Computing: QUBT, RGTI, IONQ React In Tuesday Premarket

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and lowers the price target from $50 to $44.

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Lowers Price Target to $44

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares surged by 16.7% in pre-market on Tuesday as the company&#8217;s CEO, Alex Karp, <a href="https://www.benzinga.com/markets/equities/25/02/43454250/palantir-is-making-america-more-lethal-as-alex-karp-led-company-secures-1-8-billion-in-ai-contracts-us-commercial-customer-base-surges-73">emphasized a surge in demand</a> for its artificial intelligence software, describing it as &#8220;untamed organic growth.&#8221;
What Happened: The Denver-based company&#8217;s shares ended 1.52% higher at $83.74 on Monday after which the company reported its fourth-quarter results. This surge came after Palantir forecasted revenue of $3.75 billion in 2025, surpassing analysts&#8217; estimates.
The adjusted operating income is expected to be around $1.56 billion, according to a statement released on Monday. Analysts, on average, projected revenue of $3.54 billion and an operating profit of $1.37 billion.
The company&#8217;s shares have been on an upward trajectory, with a 393.36% increase over the past year and a 9.71% increase year-to-date. Palantir stock also reached a record intraday high of $85.22 on Jan. 31, 2025.&nbsp;The strong performance is attributed to the company&#8217;s consistent ability to meet or exceed analyst estimates for six consecutive quarters.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43453280/peter-thiels-palantir-sounds-alarm-on-chinas-deepseek-citing-national-security-threat-but-says-it-wont-drop-clients-who-use-it">Palantir Sounds Alarm On China&#8217;s DeepSeek, Citing National Security Threat — But Won&#8217;t Drop Clients Who Use It</a>
Why It Matters: The surge in Palantir&#8217;s shares follows a series of positive developments for the company. On Monday, the company reported <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">fourth-quarter revenue</a> of $827.52 million, surpassing the consensus estimate of $775.91 million. This marked the sixth consecutive quarter in which Palantir met or exceeded analyst estimates. 
Palantir reported a 64% year-over-year increase in its U.S. commercial revenue, reaching $214 million, while its U.S. government revenue grew 45% to $343 million. The company anticipates U.S. commercial sales to expand by at least 54%, reaching approximately $1.08 billion in 2025.
During the company&#8217;s quarterly earnings call on Monday, CEO Karp expressed optimism about the disruption caused by Elon Musk-led DOGE. He believes it will benefit both the U.S. and Palantir, which holds major government contracts.
Additionally, market commentators Jim Cramer and Dan Ives have made bullish predictions about Palantir&#8217;s potential in the artificial intelligence revolution. Cramer cheered as the stock crossed a <a href="https://www.benzinga.com/markets/equities/25/02/43452860/palantir-soars-23-after-hours-as-cramer-says-i-wont-let-you-down-and-dan-ives-calls-it-the-next-oracle-in-ai-boom">$100 price target</a>, while Ives referred to the company as &#8220;the next Oracle in the AI boom.&#8221;
Price Action: Shares soared over 16.7% to $97.76, during the publication of this article, while the exchange-traded fund tracking Nasdaq 100, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.19% lower to $517.13.
READ MORE: <a href="https://www.benzinga.com/insights/options/25/01/43309170/palantir-technologies-options-trading-a-deep-dive-into-market-sentiment">Palantir Technologies Options Trading: A Deep Dive into Market Sentiment</a>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Movers & Shakers

PLTR Stock Surges Over 17% In Pre-Market After CEO Alex Karp Touts 'Untamed Organic Growth' In AI Demand

Shares of Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rose sharply in today's pre-market trading following better-than-expected <a href="https://in.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">fourth-quarter results</a>.
Palantir reported fourth-quarter revenue of $827.52 million, beating the consensus estimate of $775.91 million. The company reported fourth-quarter adjusted earnings of 14 cents per share, beating analyst estimates of 11 cents per share.
Palantir Technologies shares jumped 16.5% to $97.56 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) gained 72.5% to $4.14 in pre-market trading.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) rose 40.1% to $2.13 in pre-market trading after jumping more than 6% on Monday.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) gained 40% to $0.3900 in pre-market trading after gaining around 15% on Monday.</li>
<li>Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) gained 27.4% to $1.35 in pre-market trading. Invivyd shares jumped 196% on Monday after the company provided preliminary fourth-quarter PEMGARDA net product revenue results.</li>
<li>CleanCore Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#NYSE">ZONE</a>) shares jumped 25.5% to $1.28 in pre-market trading following a 3% gain on Monday.</li>
<li>Reborn Coffee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) rose 17.8% to $6.00 in pre-market trading after jumping 54% on Monday. Reborn Coffee recently announced it approve a franchisor in the U.S. and is intending to expand across the country.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares climbed 16% to $1.38 in pre-market trading.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 8% to $66.44 in pre-market trading. Tempus AI, Inc. announced it has completed its acquisition of Ambry Genetics.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) rose 7% to $16.79 in pre-market trading after adding 3% on Monday. XPeng witnessed a jump of 268% year-over-year. The company delivered 30,350 vehicles last month, marking a drop of 17.3% from December.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 28.2% to $0.3012 in pre-market trading after announcing Nasdaq delisting notice.</li>
<li>MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UOKA#NASDAQ">UOKA</a>) dipped 27.2% to $0.1730 in pre-market trading after jumping 83% on Monday.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) fell 25% to $0.7652 in today's pre-market trading after gaining 34% on Monday.</li>
<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) shares fell 22.6% to $3.90 in pre-market trading as the company priced its $3.05 million public offering of 762,500 common shares at $4/share.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares tumbled 20.2% to $0.1555 in pre-market trading. Tonix Pharmaceuticals shares dipped over 54% on Monday after the company announced a 1-for-100 reverse stock split.</li>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) fell 16.1% to $0.5335 in pre-market trading. HCW Biologics shares jumped 129% on Monday after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) fell 14.2% to $0.7166 in pre-market trading after declining around 4% on Monday.</li>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) fell 6.1% to $32.81 in pre-market trading. UBS Group reported stronger-than-expected earnings for its fourth quarter and disclosed a share buyback program of up to $3 billion.</li>
<li>Ponce Financial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDLB#NASDAQ">PDLB</a>) declined 5.3% to $12.61 in pre-market trading.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) shares dipped 5.2% to $124.31 in pre-market trading after the Chinese Ministry of Commerce added the company, along with Calvin Klein owner PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) to the unreliable entities list amid the ongoing trade war with the U.S..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

AREB

AZTR

BCTX

EVAX

HCWB

ILMN

IVVD

KAPA

PDLB

REBN

TNXP

UOKA

XPEV

ZONE

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Baird analyst Peter Arment downgrades Triumph Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) from Outperform to Neutral and raises the price target from $20 to $26.

Baird Downgrades Triumph Group to Neutral, Raises Price Target to $26

Roth MKM analyst Eric Handler upgrades AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) from Sell to Neutral and lowers the price target from $4 to $3.25.

Upgrades

Roth MKM Upgrades AMC Enter Hldgs to Neutral, Lowers Price Target to $3.25

BMO Capital analyst John Kim initiates coverage on Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announces Price Target of $71.

Initiation

TRNO

BMO Capital Initiates Coverage On Terreno Realty with Market Perform Rating, Announces Price Target of $71

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Monday.
U.S. stocks settled lower on Monday, with the Dow Jones index falling more than 100 points during the session after President Donald Trump announced plans to pause tariffs against Mexico for one month. The index dipped as much as 665.6 points earlier during the session.
Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dipped 35% on Monday after the company issued lower-than-expected fourth-quarter and FY24 preliminary revenue results. Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) posted better-than-expected first-quarter FY25 earnings results.
On the economic data front, U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November. The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December topping estimates of 49.8.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, information technology, and industrials stocks recording losses on Monday. However, utilities and consumer staples stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 123 points to 44,421.91 on Monday. The S&amp;P 500 fell 0.76% to 5,994.57, while the Nasdaq Composite fell 1.20% at 19,391.96 during Monday's session.
Investors are awaiting earnings results from Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 44.1, the index remained in the &#8220;Fear&#8221; zone on Monday, versus a prior reading of 40.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Trims Losses After Trump Delays Mexico, Canada Tariffs: Greed Index Remains In 'Fear' Zone

Raymond James analyst John Freeman initiates coverage on Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announces Price Target of $135.

Raymond James Initiates Coverage On Expand Energy with Strong Buy Rating, Announces Price Target of $135

Nuvectis gains on FDA's orphan drug designation for cancer therapy

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target...

Nuvectis Pharma (NVCT) Gets a Buy from Roth MKM

Nuvectis Pharma, Inc. ( ($NVCT) ) has released its Q3 earnings. Here is a breakdown of the information Nuvectis Pharma, Inc. presented to its inves...

Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress

Nuvectis Pharma (NVCT) reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovari...

Nuvectis Pharma reports data from Phase 1b study of NXP800

09:46 EST Nuvectis Pharma (NVCT) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

Nuvectis Pharma Inc trading resumes

09:41 EST Nuvectis Pharma (NVCT) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market...

Nuvectis Pharma Inc trading halted, volatility trading pause

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target of $21.00...

Positive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy Rating

Nuvectis sinks after early-stage data for ovarian cancer therapy

New option listings for December 18th include AKTSQ Stock (AKTSQ), Brainsway LTD (BWAY), Nuvectis Pharma Inc (NVCT), Performant Healthcare Inc. (PH...

Six new option listings and two option delistings on December 18th

Nuvectis Pharma: Still Flat, Although There May Be A Ground Floor Here

AKTS

BRSYF

BWAY

NVCT

PFMT

PRTH

TTAN

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit's Meteoric Rise: Silexion, Nuvectis, Scorpian

Press Releases

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Comments

Nuvectis Pharma

Nuvectis Pharma (NVCT) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル